Picture of Angle logo

AGL Angle Share Price

0.000.00%
gb flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapSucker Stock

Momentum

Relative Strength (%)
1m-37.06%
3m-47.98%
6m-39.35%
1yr-52.04%
Volume Change (%)
10d/3m+39.06%
Price vs... (%)
52w High-79.24%
50d MA-36.29%
200d MA-48.49%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-68.33%
Return on Equity-63.75%
Operating Margin-959.88%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202431st Dec 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Angle EPS forecast chart

Profile Summary

ANGLE plc is a United Kingdom-based liquid biopsy company with circulating tumor cell (CTC) solutions for use in research, drug development and clinical oncology using a simple blood sample. Its circulating tumor cell (CTC) harvesting technology known as the Parsortix PC1 System enables complete downstream analysis of the sample, including whole cell imaging and proteomic analysis and full genomic and transcriptomic molecular analysis. The Parsortix PC1 system is a medical device for the capture and harvest of intact CTCs from metastatic breast cancer (MBC) patient blood for user-validated analysis. Its commercial businesses focus on diagnostic products and clinical services. Its diagnostic products include the Parsortix system and associated consumables. Its services include custom made assay development and clinical trial testing for pharma. The Parsortix technology uses a microfluidic technology in the form of a single use cassette to capture and then harvest CTCs from whole blood.

Directors

Last Annual
December 31st, 2023
Last Interim
June 30th, 2024
Incorporated
December 4th, 2003
Public Since
March 17th, 2004
No. of Employees
150
Sector
Healthcare Equipment & Supplies
Industry
Healthcare
Exchange
gb flag iconLondon Stock Exchange
Shares in Issue
322,641,668

AGL Share Price Performance

Similar to AGL

Picture of Abingdon Health logo

Abingdon Health

gb flag iconLondon Stock Exchange

Picture of Advanced Medical Solutions logo

Advanced Medical Solutions

gb flag iconLondon Stock Exchange

Picture of Aoti logo

Aoti

gb flag iconLondon Stock Exchange

Picture of Aptamer logo

Aptamer

gb flag iconLondon Stock Exchange

Picture of Belluscura logo

Belluscura

gb flag iconLondon Stock Exchange

FAQ